Jerry M. Collins, Ph.D., is an internationally recognized pharmacologist. He has been closely associated with NCI’s drug development efforts for more than 25 years, first as an NCI intramural investigator and then as the Chief of the Pharmacokinetics Section. From 1988 until 2005, Dr. Collins served as the Director of the FDA’s Laboratory of Clinical Pharmacology, where he headed the development of new methods to facilitate research on human tissue metabolism to create an in vitro model to reduce adverse drug reactions. More…
The Developmental Therapeutics Program (DTP), originally created by Congress in 1955 as the Cancer Chemotherapy National Service Center, serves as a vital resource for preclinical information and research materials, including web-accessible data and tools, NCI-60 Tumor Cell Line Screen, compounds in vials and plates, tumor cells, animals, and bulk drugs for investigational new drug (IND)-directed studies.
Since its establishment, DTP has played an intimate role in the discovery or development of more than 40 U.S.-licensed chemotherapeutic agents, with the rest coming directly from the pharmaceutical industry. On that list is Paclitaxel, one of the most widely prescribed anticancer drugs on the market. Paclitaxel, a natural product, was first discovered by researchers working under a joint U.S. Department of Agriculture-National Cancer Institute grant. It was a DTP contractor who formulated the drug for use in clinical trials. Bortezomib is another DTP success story. In cooperation with its commercial sponsor, bortezomib was screened and formulated by DTP. Approved by the Food and Drug Administration (FDA) in 2003, it was the first treatment in more than a decade to be approved for patients with multiple myeloma. More recent successes include romidepsin (approved in 2009 for cutaneous T-cell lymphoma), eribulin (approved in 2010 for metastatic breast cancer), and sipuleucel-T (approved in 2010 for prostate cancer).
Many academic and private industry laboratories engaged in drug discovery often face financial and technical burdens that keep promising therapeutic agents from reaching patients. DTP has been involved in the discovery or development of more than 70 percent of the anticancer therapeutics on the market today, and will continue helping the academic and private sectors to overcome various therapeutic development barriers, particularly through supporting high-risk projects and therapeutic development for rare cancers.
DTP’s staff and administered grants are divided among ten components:
Year | Drug Name(s) | Year | Drug Name(s) |
---|---|---|---|
2010 | Eribulin (NSC 707389) Sipuleucel-T (NSC 720270) |
1979 | Daunorubicin (NSC 82151) |
2009 | Romidepsin (NSC 630176) | 1978 | Cisplatin (cis-platinum) (NSC 119875) |
2004 | Erbitux (NSC 632307) | 1977 | BCNU (NSC 409962) |
2003 | Velcade (NSC 681239) | 1976 | CCNU (NSC 9037) |
1998 | Ontak (NSC 697979) | 1975 | Dacarbazine (NSC 45388) |
1996 | Gliadel (NSC 714372) Topotecan (NSC 609699) |
1974 | Adriamycin (NSC 123127) Mitomycin C (NSC 26980) |
1995 | All-t-retinoic acid (NSC 122758) | 1973 | Bleomycin (NSC 125066) |
1992 | Chorodeoxyadenosine (NSC 105014) Taxol (NSC 125973) Teniposide (NSC 122819) |
1970 | FUDR (NSC 27640) Mithramycin (NSC 24559) o-p'-DDD (NSC 38721) |
1991 | Fludarabine Phosphate (NSC 312887) Pentostatin (NSC 218321) |
1969 | Ara-C (NSC 63878) Procarbazine (NSC 77213) |
1990 | Hexamethylmelamine (NSC 13875) Levamisole (NSC 177023) |
1967 | Hydroxyurea (NSC 32065) |
1989 | Carboplatin (NSC 241240) | 1966 | Pipobroman (NSC 25154) Thioguanine (NSC 752) |
1988 | Ifosfamide (NSC 109724) | 1964 | Melphalan (NSC 8806) Actinomycin D (NSC 3053) |
1987 | Mitoxantrone (NSC 301739) | 1963 | Vincristine (NSC 67574) |
1983 | Etoposide (NSC 141540) | 1962 | Fluorouracil (NSC 19893) |
1982 | Streptozotocin (NSC 85998) | 1961 | Vinblastine (NSC 49842) |
1959 | Cyclophosphamide (NSC 26271) Thiotepa (NSC 6396) |
||
1957 | Chlorambucil (NSC 3088) |